Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2143675 | 0.83 | CYP2D6 (0.31) | — | |
| SCHEMBL1858220 | 0.81 | DGAT1 (0.40) | DGAT1 | |
| SCHEMBL1396124 | 0.80 | DGAT1 (0.37) | DGAT1NPC1 | |
| SCHEMBL24766780 | 0.80 | DGAT1 (0.37) | DGAT1 | |
| SCHEMBL14859021 | 0.80 | DGAT1 (0.42) | DGAT1 | |
| SCHEMBL31631869 | 0.79 | DGAT1 (0.36) | DGAT1 | |
| SCHEMBL5767723 | 0.78 | CYP11B1 (0.38) | DGAT1NPC1 | |
| SCHEMBL4068886 | 0.78 | DGAT1 (0.38) | DGAT1 | |
| SCHEMBL26693782 | 0.77 | CYP11B1 (0.51) | DGAT1 | |
| SCHEMBL5767022 | 0.76 | CYP11B1 (0.40) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4608835-A1 | PURINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Novo Nordisk A/S (DK) | 2025-09-03 | — | — | EP | disclosed |
| WO-2025125665-A1 | FURTHER SUBSTITUTED IMIDAZOLES AS INHIBITORS OF NAV1.8 | Grünenthal GmbH (DE) | 2025-06-19 | — | — | WO | disclosed |
| CN-120129684-A | Purine compound, composition containing same and use thereof | 诺和诺德股份有限公司 | 2025-06-10 | — | — | CN | disclosed |
| WO-2025021182-A1 | CYP11A1 INHIBITORS | ACERAND THERAPEUTICS (HONG KONG) LIMITED (CN) | 2025-01-30 | — | — | WO | disclosed |
| WO-2024086939-A1 | PURINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | INVERSAGO PHARMA INC. (CA) | 2024-05-02 | — | — | WO | disclosed |
| US-20240043435-A1 | TYK-2 INHIBITOR | BEONE MEDICINES I GMBH (CH) | 2024-02-08 | — | — | US | disclosed |
| EP-4168398-A1 | TYK-2 INHIBITOR | BeiGene, Ltd. (KY) | 2023-04-26 | — | — | EP | disclosed |
| CN-115715288-A | TYK-2 inhibitors | 百济神州有限公司 | 2023-02-24 | — | — | CN | disclosed |
| US-11530200-B2 | Compounds | INFLAZOME LIMITED (IE) | 2022-12-20 | — | — | US | disclosed |
| US-20210047302-A1 | NOVEL COMPOUNDS | INFLAZOME LIMITED (IE) | 2021-02-18 | — | — | US | disclosed |
| US-20210002274-A1 | NOVEL COMPOUNDS | INFLAZOME LIMITED (IE) | 2021-01-07 | — | — | US | disclosed |
| US-9840507-B2 | 5,6-dihydro-imidazo[1,2-a]pyrazin-8-ylamine derivatives useful as inhibitors of beta-secretase (BACE) | JANSSEN PHARMACEUTICA, NV (BE) | 2017-12-12 | — | — | US | disclosed |
| US-9840507-B2 | 5,6-dihydro-imidazo[1,2-a]pyrazin-8-ylamine derivatives useful as inhibitors of beta-secretase (BACE) | JANSSEN PHARMACEUTICA, NV (BE) | 2017-12-12 | — | — | US | disclosed |
| EP-2655376-B1 | 5,6-DIHYDRO-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-23 | — | — | EP | disclosed |
| EP-2655376-A1 | 5,6-DIHYDRO-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | Janssen Pharmaceutica NV (BE) | 2013-10-30 | — | — | EP | disclosed |
| US-20130274266-A1 | 5,6-DIHYDRO-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2013-10-17 | — | — | US | disclosed |
| US-20130274266-A1 | 5,6-DIHYDRO-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2013-10-17 | — | — | US | disclosed |
| US-20130274266-A1 | 5,6-DIHYDRO-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2013-10-17 | — | — | US | disclosed |
| WO-2012085038-A1 | 5,6-DIHYDRO-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210047302-A1 | NOVEL COMPOUNDS | NLRP3, NOD1, CBR3 | DGAT1 3577/4885NPC1 98/4885 |
| US-20240043435-A1 | TYK-2 INHIBITOR | TYK2, IRAK2, PTK2B | DGAT1 3328/4885NPC1 4606/4885 |
| US-20130274266-A1 | 5,6-DIHYDRO-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | BACE2, BACE1, PSEN2 | DGAT1 2615/4885NPC1 2171/4885 |
| US-20210002274-A1 | NOVEL COMPOUNDS | NLRP3, NOD1, NLRP1 | DGAT1 3742/4885NPC1 58/4885 |
| US-11530200-B2 | Compounds | NLRP3, NOD1, NLRP1 | DGAT1 3710/4885NPC1 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.